enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases $15,660.00 in Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Sanjay Shrivastava acquired 5,400 shares of the firm’s stock in a transaction that occurred on Tuesday, December 24th. The stock was purchased at an average cost of $2.90 per share, with a total value of $15,660.00. Following the purchase, the director now directly owns 9,288 shares in the company, valued at approximately $26,935.20. This trade represents a 138.89 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

enVVeno Medical Stock Up 2.9 %

NVNO opened at $3.15 on Friday. enVVeno Medical Corporation has a 12-month low of $2.45 and a 12-month high of $6.97. The firm has a market capitalization of $55.24 million, a P/E ratio of -2.44 and a beta of 1.22. The stock has a fifty day moving average of $3.19 and a 200-day moving average of $4.30.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). On average, analysts expect that enVVeno Medical Corporation will post -1.3 earnings per share for the current fiscal year.

Institutional Trading of enVVeno Medical

Several institutional investors have recently made changes to their positions in the stock. Hohimer Wealth Management LLC acquired a new position in enVVeno Medical in the 3rd quarter valued at approximately $286,000. Maven Securities LTD purchased a new position in shares of enVVeno Medical during the 3rd quarter valued at $295,000. Westside Investment Management Inc. increased its stake in shares of enVVeno Medical by 128.0% in the third quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock worth $297,000 after acquiring an additional 49,613 shares during the last quarter. Corsair Capital Management L.P. purchased a new stake in shares of enVVeno Medical during the third quarter worth $390,000. Finally, Geode Capital Management LLC boosted its position in enVVeno Medical by 7.8% during the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock valued at $506,000 after purchasing an additional 10,902 shares during the last quarter. 34.71% of the stock is currently owned by institutional investors and hedge funds.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).